Clinical Trials Logo

Cirrhosis clinical trials

View clinical trials related to Cirrhosis.

Filter by:

NCT ID: NCT00888784 Completed - Cirrhosis Clinical Trials

Secondary Prophylaxis Gastric Variceal Bleed

Start date: August 2006
Phase: N/A
Study type: Interventional

The investigators conducted a randomized, controlled trial (RCT) to study the efficacy of beta blockers versus endoscopic cyanoacrylate injection in the prevention of gastric variceal (GOV2 or IGV1) rebleeding and improvement in survival.

NCT ID: NCT00883454 Completed - Clinical trials for Hepatocellular Carcinoma

Estimation of Functional Liver Reserve Using Cholinesterases

Start date: n/a
Phase: N/A
Study type: Observational

Estimation of functional liver reserve in patients with hepatocellular carcinoma (HCC) in cirrhosis is of paramount importance to properly select candidates for surgical resection. Together with the value of bilirubin, the presence/absence of ascites and esophageal varices, and the rate of residual liver volume, which are our current parameters to measure functional liver reserve, the investigators sought to investigate the value of preoperative cholinesterases (CHE) in predict postoperative adverse outcome after hepatic resection for HCC.

NCT ID: NCT00820781 Completed - Cirrhosis Clinical Trials

Endoscopic Sclerotherapy and/or Ligation Versus Portacaval Shunt for Bleeding Gastric Varices

Start date: August 1977
Phase: N/A
Study type: Interventional

In unselected cirrhotic patients with bleeding gastric varices to compare the influence on mortality rate, duration of life, control of bleeding, quality of life, and economic costs of treatment of: portacaval shunt, endoscopic variceal sclerotherapy and/or variceal ligation.

NCT ID: NCT00802555 Completed - Clinical trials for Hepatocellular Carcinoma

Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)

Start date: January 2009
Phase: Phase 1
Study type: Interventional

Multi-center, single-arm Phase 1b study designed to evaluate safety and tolerability of ARQ 197 in cirrhotic patients with HCC.

NCT ID: NCT00772057 Completed - Cirrhosis Clinical Trials

Beta-blockers for Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: An Randomized Controlled Trial (RCT)

Start date: October 2004
Phase: N/A
Study type: Interventional

Background and Aims: The efficacy of portal pressure reduction by beta blockers for the management of small (≤5 mm) esophageal varices in patients of cirrhosis is not clear. The present randomized controlled trial aims to address these issues. The investigators also assessed the utility of serial HVPG measurements in these patients. Patients and Methods: Consecutive patients with cirrhosis with small varices, with no history of variceal bleed, were randomized to receive propranolol or placebo. These patients were further randomized to undergo no HVPG, only baseline HVPG, or serial HVPG measurement. Propranolol was titrated to reduce heart-rate to 55/min.

NCT ID: NCT00764049 Completed - Cirrhosis Clinical Trials

Single Pass Albumin Dialysis in Patients With Cirrhosis

DACAR
Start date: June 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to determine whether a simplified device of albumin dialysis also has beneficial effects.

NCT ID: NCT00741663 Completed - Cirrhosis Clinical Trials

Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)

SVSSF
Start date: April 2005
Phase: Phase 4
Study type: Interventional

The question whether the sequential diuretic therapy, that means using an antialdosteronic drug at first and adding a loop diuretic in nonresponders, is better than the combination of the two diuretics from the beginning (combined diuretic therapy) in the treatment of ascites in patients with cirrhosis is still open. Therefore, the aim of the study is to compare sequential versus combined diuretic therapy in these patients. One hundred patients will be randomized into two groups. Group A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day. Group B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively. The percentage of responders to dthe diuretic treatment, the time to get the resolution of ascites and the rate of adverse effects will be compared between the two Groups of Patients.

NCT ID: NCT00713934 Completed - Cirrhosis Clinical Trials

Autologous Bone Marrow Stem Cells in Cirrhosis Patients

Start date: January 2008
Phase: Phase 1/Phase 2
Study type: Interventional

Liver cirrhosis (LC) is the end stage of chronic liver disease. The liver transplantation is one of the only effective therapies available to such patients. However, lack of donors, surgical complications, rejection, and high cost are it`s serious problems. The potential for stem cells in bone marrow (BM) to differentiate into hepatocytes cells was recently confirmed. Moreover, BMC transplantation has been performed to treat hematological diseases, and several clinical studies have applied BMC injection to induce regeneration of myocardium and blood vessels. In this study we will evaluate safety and feasibility of autologous bone marrow mono nuclear (BM-MNC) and enriched CD133+ hematopoietic stem cell transplantation through the portal vein in patients with decompensate cirrhosis.

NCT ID: NCT00701792 Completed - Cirrhosis Clinical Trials

Liver Transplantation Versus Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis

TRANSCIAL
Start date: March 1994
Phase: N/A
Study type: Interventional

Liver transplantation has been universally recognized to improve survival of patients suffering from end-stage (Pugh C) alcoholic cirrhosis. However, for Pugh B patients, the benefit of liver transplantation remains to be demonstrated. The aim of the present study was to compare the outcome of Pugh B patients with alcoholic cirrhosis randomly assigned for immediate liver transplantation (group 1) or standard treatments (group 2).

NCT ID: NCT00629421 Completed - Clinical trials for Hepatocellular Carcinoma

Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study

Start date: January 1, 2001
Phase: N/A
Study type: Observational

Although serum alpha-fetoprotein level and abdominal sonography are the main methods to screening hepatocellular carcinoma (HCC) in cirrhotic patients, the adequate time and methods used are not completely well-defined. This study aims to assess the better timing and methods for prospectively screening HCC in patients with cirrhosis